172 related articles for article (PubMed ID: 31429898)
21. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation.
Kauff ND; Satagopan JM; Robson ME; Scheuer L; Hensley M; Hudis CA; Ellis NA; Boyd J; Borgen PI; Barakat RR; Norton L; Castiel M; Nafa K; Offit K
N Engl J Med; 2002 May; 346(21):1609-15. PubMed ID: 12023992
[TBL] [Abstract][Full Text] [Related]
22. Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility.
Wolff TA; Wilson JE
Am Fam Physician; 2006 Nov; 74(10):1759-60. PubMed ID: 17137007
[No Abstract] [Full Text] [Related]
23. Summaries for patients. Assessing the genetic risk for BRCA-related breast or ovarian cancer in women: recommendations from the U.S. Preventive Services Task Force.
Ann Intern Med; 2014 Feb; 160(4):I-16. PubMed ID: 24366402
[No Abstract] [Full Text] [Related]
24. The more you look, the more you will find.
Walsh CS
Cancer; 2016 Jan; 122(1):14-6. PubMed ID: 26439222
[No Abstract] [Full Text] [Related]
25. [Not Available].
Gladieff L; Lyonnet DS; Lortholary A; Leary A; Genestie C; Ray-Coquard I
Bull Cancer; 2017 May; 104 Suppl 1():S16-S23. PubMed ID: 28625311
[TBL] [Abstract][Full Text] [Related]
26. BRCA1 and BRCA2 cancer risks.
Antoniou AC; Pharoah PD; Easton DF; Evans DG
J Clin Oncol; 2006 Jul; 24(20):3312-3; author reply 3313-4. PubMed ID: 16829658
[No Abstract] [Full Text] [Related]
27. Video-assisted genetic counseling in patients with ovarian, fallopian and peritoneal carcinoma.
Watson CH; Ulm M; Blackburn P; Smiley L; Reed M; Covington R; Bokovitz L; Tillmanns T
Gynecol Oncol; 2016 Oct; 143(1):109-112. PubMed ID: 27416795
[TBL] [Abstract][Full Text] [Related]
28. Clinical outcomes of BRCA1/2 pathogenic variants in ovarian cancer cluster region in patients with primary peritoneal, epithelial ovarian, and fallopian tube cancer.
Ha HI; Park EY; Eoh KJ; Lee YJ; Seo SS; Kang S; Park SY; Lim MC
Gynecol Oncol; 2022 Feb; 164(2):415-420. PubMed ID: 34924242
[TBL] [Abstract][Full Text] [Related]
29. Decisions and ethical issues among BRCA carriers and the use of preimplantation genetic diagnosis.
Quinn GP; Vadaparampil ST; Bower B; Friedman S; Keefe DL
Minerva Med; 2009 Oct; 100(5):371-83. PubMed ID: 19910890
[TBL] [Abstract][Full Text] [Related]
30. BRCA 1/2-negative patients who receive counseling after genetic testing have lower anxiety.
Printz C
Cancer; 2016 Apr; 122(8):1149. PubMed ID: 27061519
[No Abstract] [Full Text] [Related]
31. Pros and cons of screening for BRCA mutations.
Howard-McNatt M
N C Med J; 2013; 74(6):489-90. PubMed ID: 24316772
[No Abstract] [Full Text] [Related]
32. One risk fits all?
De Bock GH; Mourits MJ; Oosterwijk JC
J Clin Oncol; 2007 Aug; 25(22):3383-4; author reply 3384. PubMed ID: 17664491
[No Abstract] [Full Text] [Related]
33. Prevention and screening in BRCA mutation carriers and other breast/ovarian hereditary cancer syndromes: ESMO Clinical Practice Guidelines for cancer prevention and screening.
Paluch-Shimon S; Cardoso F; Sessa C; Balmana J; Cardoso MJ; Gilbert F; Senkus E;
Ann Oncol; 2016 Sep; 27(suppl 5):v103-v110. PubMed ID: 27664246
[No Abstract] [Full Text] [Related]
34. Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: recommendation statement.
U.S. Preventive Services Task Force
Ann Intern Med; 2005 Sep; 143(5):355-61. PubMed ID: 16144894
[TBL] [Abstract][Full Text] [Related]
35. Peritoneal carcinoma in women with genetic susceptibility: implications for Jewish populations.
Casey MJ; Bewtra C
Fam Cancer; 2004; 3(3-4):265-81. PubMed ID: 15516851
[TBL] [Abstract][Full Text] [Related]
36. Hereditary Breast and ovarian cancer: providing personalized medicine.
Tranin AS
AWHONN Lifelines; 2005; 9(5):372-6. PubMed ID: 16359075
[No Abstract] [Full Text] [Related]
37. High-risk women should have BRCA testing.
Cancer Discov; 2014 Feb; 4(2):139. PubMed ID: 24501290
[TBL] [Abstract][Full Text] [Related]
38. Genetic risk assessment and BRCA mutation testing.
Ormond KE; Bellcross C; Weissman S
Ann Intern Med; 2006 Feb; 144(4):303-4; discussion 304. PubMed ID: 16490919
[No Abstract] [Full Text] [Related]
39. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases.
Pal T; Permuth-Wey J; Betts JA; Krischer JP; Fiorica J; Arango H; LaPolla J; Hoffman M; Martino MA; Wakeley K; Wilbanks G; Nicosia S; Cantor A; Sutphen R
Cancer; 2005 Dec; 104(12):2807-16. PubMed ID: 16284991
[TBL] [Abstract][Full Text] [Related]
40. Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: systematic evidence review for the U.S. Preventive Services Task Force.
Nelson HD; Huffman LH; Fu R; Harris EL;
Ann Intern Med; 2005 Sep; 143(5):362-79. PubMed ID: 16144895
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
